• 1
    Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003; 3: 8192.
  • 2
    Sachar D, Andrews HA, Farmer RG, et al. Proposed classification of patient subgroups in Crohn's disease. Gastroenterology Int 1992; 5: 14154.
  • 3
    Shivananda S, Lennard-Jones J, Logan R, et al. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39: 6907.
  • 4
    Pajares JM, Gisbert JP. Epidemiology of inflammatory bowel disease in Spain. A systematic review. Rev Esp Enferm Dig 2001; 93: 920.
  • 5
    Saro Gismera C, Lacort Fernandez M, Arguelles Fernandez G, et al. Incidencia y prevalencia de la enfermedad inflamatoria intestinal en Gijón, Asturias, España. Gastroenterol Hepatol 2000; 23: 3227.
  • 6
    Juan J, Estiarte R, Colome E, et al. Burden of illness of Crohn's disease in Spain. Dig Liver Dis 2003; 35: 85361.
  • 7
    Hanauer SB. Measurement of disease activity. In: TarganSR, ShanahanF, eds. Inflammatory Bowel Disease: from Bench to Bedside. Baltimore, MD: Williams & Wilkins, 1994: 42944.
  • 8
    Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 2005; 65: 225386.
  • 9
    Sicilia B, Lopez Miguel C, Arribas F, et al. Environmental risk factors and Crohn's disease: a population-based, case-control study in Spain. Dig Liver Dis 2001; 33: 7627.
  • 10
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 102935.
  • 11
    Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999; 117: 7619.
  • 12
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398405.
  • 13
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 14
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 87685.
  • 15
    Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 40213.
  • 16
    Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 6018.
  • 17
    Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 91724.
  • 18
    Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 54253.
  • 19
    Breedveld FC. Therapeutic monoclonal antibodies. Lancet 2000; 355: 73540.
  • 20
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 32333.
  • 21
    Sandborn WJ, Hanauer SB, Lukas M, et al. Induction and maintenance of clinical remission and response in subjects with Crohn's disease treated during a 6-month open-label period with fully human anti-TNF-α monoclonal antibody adalimumab (Humira®). Gastroenterology 2005; 128 (Suppl. 2): A111 (abstract 723).
  • 22
    Papadakis KA, Shaye OA, Vasiliauskas EA, et al. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol 2005; 100: 759.
    Direct Link:
  • 23
    Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99: 19849.
    Direct Link:
  • 24
    Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004; 10: 3338.
  • 25
    Barthel HR, Gille T, Halbsguth A, et al. Successful treatment with adalimumab in infliximab-resistant Crohn's disease. J Gastroenterol Hepatol 2005; 20: 14645.
  • 26
    Stallmach A, Giese T, Schmidt C, et al. Severe anaphylactic reaction to infliximab: successful treatment with adalimumab – report of a case. Eur J Gastroenterol Hepatol 2004; 16: 62730.
  • 27
    Best W, Becktel J, Singleton J, et al. Development of a Crohn's Disease Activity Index: National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 43944.
  • 28
    Hodgson HJF, Mazlam MZ. Assessment of drug therapy in inflammatory bowel disease. Aliment Pharmacol Ther 1991; 5: 55584.
  • 29
    Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995; 20: 2732.